Belgium's high-tech pharmaceutical product imports have shown notable growth from 2013 to 2023, rising from 14.04 billion Euros to 33.98 billion Euros. Year-on-year variations over the last two years indicate a deceleration in growth with increases of 5.98% in 2022 and 5.61% in 2023. The compound annual growth rate (CAGR) over the last five years stands at 10.59%, showcasing a robust upward trend in the import of these products.

Looking towards the future, the forecast data suggests a continued upward trajectory, reaching 42.75 billion Euros by 2028. However, the anticipated CAGR for the next five years is predicted to slow to 3.63%, indicating a more moderate growth pace. The overall forecasted growth rate over five years stands at 19.5%.

Future trends to watch for include:

Technological advancements in pharmaceutical research and development.
Regulatory changes impacting import policies and market access.
Shifts in global supply chains and their potential effects on import volumes and values.
Increased focus on biologics and personalized medicine driving specific import segments.